Although mortality from infectious disease has declined globally, viral and bacterial infections still disproportionately impact the world's most vulnerable populations. Pneumonia and diarrhoea are major killers in young children while syphilis is the main cause of stillbirth and perinatal mortality. HIV, tuberculosis, and viral hepatitis are among the leading causes of deaths due to infectious disease in adults living in low and middle income countries. Treatment for these devastating diseases exists, but their use and effectiveness face numerous challenges including timely diagnosis, drug resistance and access to healthcare. Sub-Saharan Africa is home to 70% of the world’s people living with HIV and the highest tuberculosis burden in the world. Although treatment has saved many lives, daunting challenges in reaching, diagnosing and treating patients hamper their control.
Multi-resistant bacteria are found in all regions of the world and spread easily, thus constituting one of the most serious threats to global health. In the last decades, emerging infectious diseases, especially those related to emerging viruses such as dengue, chikungunya and Zika, have become an increasingly important area of concern in public health at a global level. The crisis triggered by SARS-CoV-2, the coronavirus responsible for COVID-19, has brought the threat of emerging viruses to the forefront at a global level.
Main research lines
At ISGlobal, we use our experience to improve the diagnosis and treatment of viral and bacterial diseases, to understand the causes of antibiotic resistance, and to find novel ways of reaching underserved populations in the following areas:
- Jordi Vila Research Professor, Director of the Antimicrobial Resistance Initiative and Head of the Viral and Bacterial Infections Programme
- Denise Suzanne Naniche Scientific Director
- Enrique Bassat Orellana
- Climent Casals-Pascual Associate Research Professor
- Alberto García-Basteiro Assistant Research Professor
- Julià González Associated Researcher
- Jeffrey Lazarus Associate Research Professor
- Emili Letang Associated Researcher
- Mª Angeles Marcos Maeso
- Miguel J. Martínez Associated Researcher
- Ignasi Roca Subira
- Sara Soto Associate Research Professor
- Antoni Trilla Research Professor, Dean of the Faculty of Medicina and Health Sciences, UB
Application to medical devices
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
Integrating and decentralizing diabetes and hypertension services in Africa
Conèixer la propagació. Entendre la protecció
A breakthrough device for the rapid detection of antimicrobial resistance
Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19
Other projectsSee Past Projects
Combating Bacterial Resistance In Europe
Prioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission